These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4677070)

  • 21. The syntheses and substrate specificity for mammalian dihydroxyphenylalanine decarboxylase of 3-, 4-, 5-, and 6-methyl-2-hydroxyphenylalanines and the substrate specificity of 3-, 5-, and 6-methyl-2,4-dihydroxyphenylalanines for the enzyme.
    Bower RH; Lambooy JP
    J Med Chem; 1969 Nov; 12(6):1028-30. PubMed ID: 5351443
    [No Abstract]   [Full Text] [Related]  

  • 22. Mutation of cysteine 111 in Dopa decarboxylase leads to active site perturbation.
    Dominici P; Moore PS; Castellani S; Bertoldi M; Voltattorni CB
    Protein Sci; 1997 Sep; 6(9):2007-15. PubMed ID: 9300500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 24. [DOPA-DOPP-transaminases of rat brain in vitro].
    Gey KF
    Helv Physiol Pharmacol Acta; 1967; 25(2):CR187-9. PubMed ID: 5588161
    [No Abstract]   [Full Text] [Related]  

  • 25. Automated radiometric assays of enzymatic and nonenzymatic oxidation of DOPA in vitro.
    Tran N
    J Lab Clin Med; 1974 Aug; 84(2):287-91. PubMed ID: 4843233
    [No Abstract]   [Full Text] [Related]  

  • 26. ON FORMATION OF NORADRENALINE IN THE SKIN: ACTIVITY OF DOPAMINE-BETA-OXIDASE.
    MOELLER H
    Acta Derm Venereol; 1963; 43():548-51. PubMed ID: 14088645
    [No Abstract]   [Full Text] [Related]  

  • 27. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J
    Rev Neurol (Paris); 1970 Apr; 122(4):243-8. PubMed ID: 5472041
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 29. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endotoxin-induced suppression of rabbit kidney DOPA decarboxylase activity.
    Fritz H; Håkanson R
    Acta Physiol Scand; 1971 Jul; 82(3):300-9. PubMed ID: 4108401
    [No Abstract]   [Full Text] [Related]  

  • 31. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ; Porter CC
    J Pharmacol Exp Ther; 1970 Apr; 172(2):406-15. PubMed ID: 5441162
    [No Abstract]   [Full Text] [Related]  

  • 32. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 33. [On the possibility of using 3-(3,4-dihydroxyphenyl)-alanine (DOPA) as a mediator of radioisotopes in a melanoma].
    Vdovenko VM; Ivanov II; Bobrova VN; Gavrilenko IS; Ivanov AI; Solov'ev AL; Rumiantseva LN
    Dokl Akad Nauk SSSR; 1965 Sep; 164(1):95-8. PubMed ID: 5872562
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 35. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.
    Opacka-Juffry J; Brooks DJ
    Mov Disord; 1995 May; 10(3):241-9. PubMed ID: 7651438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ethanol on tryptophan hydroxylase activity from striate synaptosomes.
    Rogawski MA; Knapp S; MAndell AJ
    Biochem Pharmacol; 1974 Jul; 23(14):1955-62. PubMed ID: 4418689
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of L-DOPA and structurally related compounds on blood pressure.
    Henning M; Rubenson A
    Acta Pharmacol Toxicol (Copenh); 1970; 28(1):50. PubMed ID: 5314423
    [No Abstract]   [Full Text] [Related]  

  • 38. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new assay for DOPA decarboxylase activity.
    Borri Voltattorni C; Minelli A; Turano C
    Ital J Biochem; 1974; 23(3):175-82. PubMed ID: 4425367
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of transition metals and of metal-binding antihypertensive agents on tryptamine oxidase and dopa decarboxylase.
    Perry HM; Schwartz PL; Sahagian BM
    Proc Soc Exp Biol Med; 1969 Jan; 130(1):273-7. PubMed ID: 5762508
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.